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A single butterfly flapping its wings today produces a tiny
change in the state of the atmosphere . . .
Chaos: Making a New Science, James Gleick (1)
Because of the cumulative effect of inherited minute alter-
ations of multiple genes, what the cardiovascular system
actually does over a lifetime wanders away from what it
would have done. In other words, a dreadful process of
atherosclerosis that would have devastated the cardiovascu-
lar system of an individual does not happen, or maybe one
that was not going to happen does. What was seemingly too
complex to predict, the genetic contribution to the devel-
opment of complex traits like atherosclerosis and other
common forms of cardiovascular disease, might become
affordable. We owe this new opportunity in part to the
ability to sequence the human and related genomes. Single
nucleotide polymorphisms (SNPs) represent the most fre-
quent and simplest alteration of this sequence. Unprece-
dented efforts are underway to identify both SNPs and more
complex polymorphisms and to establish their relationship
to susceptibility for common ailments and to drug response
for patients with heart disease.
See page 1023
Ischemic heart disease and adverse events following
revascularization procedures represent a complex interaction
of vascular injury, inflammation and thrombosis. Within the
past decade, however, our understanding of ischemic heart
disease has become even more sophisticated as recent
discoveries have revealed the influence of gene variants on
the development of atherosclerotic disease and arterial
thrombosis. The pioneers of the field have already studied
inherited variants affecting genes involved in processes
relevant to atherosclerosis, ranging from cholesterol metab-
olism to arterial thrombosis. Based on this information,
scientists and cardiologists have become increasingly aware
that ischemic heart disease represents a polygenic disorder.
Furthermore, we have realized that the impact of these
genes is mediated by the presence of SNPs, in a context of
environmental factors that can influence their penetrance
vis-a`-vis the disease process.
The role of platelets in unstable coronary syndromes and
adverse events following coronary intervention are typical
examples of the interplay between genetic and environmen-
tal factors. First, platelet activation is dependent upon
exposure to disrupted endothelium, circulating cytokines
and other agonists released during plaque rupture or vascu-
lar injury during angioplasty. Second, a number of genetic
polymorphisms within the subunits of platelet receptors
may also induce gain or loss of function, thereby predispos-
ing some individuals to thrombotic events. Gain or loss of
function may be secondary to polymorphisms that either
encode a missense mutation (the resulting codon provokes a
change in amino acid) or modify the level of expression of
the gene product. Although the mechanism of platelet
activation and thrombus formation is generally well estab-
lished, much controversy remains whether individual plate-
let polymorphisms contribute to an increased likelihood of
ischemic events. In this issue of the Journal, Meisel et al. (2)
have studied the association of a platelet receptor variant
with acute coronary syndromes and adverse events following
percutaneous coronary interventions.
PLATELET POLYMORPHISMS
IN ISCHEMIC HEART DISEASE
The major platelet membrane glycoproteins (GP) involved
in primary hemostasis are: 1) GPIb-IX-V, the von Wille-
brand factor (vWf) receptor responsible for initial platelet
adhesion to the subendothelium; 2) GPIIb-IIIa, the fibrin-
ogen receptor that cross-links adjacent platelets and is
required for platelet aggregation; and 3) GPIa-IIa, the
collagen receptor that stabilizes platelet adhesion.
The GPIb polymorphisms. In the event of endothelial
injury and exposure to the vWf-rich subendothelial matrix,
the GPIb-IX-V complex is responsible for securing platelets
to the vessel wall under conditions of high shear stress (Fig.
1). Specifically, the alpha chain of GPIb, GPIba, is capable
of binding both vWf and thrombin. Glycoprotein Iba
contains two known polymorphisms that affect the struc-
ture, and a third polymorphism that may alter gene expres-
sion of this subunit of the vWf receptor. The first (Ko
polymorphism) involves a single cytosine (C) to thymidine
(T) substitution in the GPIba gene at nucleotide 434,
resulting in the amino acid methionine at position 145 in
place of threonine. The second polymorphism is due to a
variable number of tandem repeats (VNTR) in a 39 base
pair sequence that codes for a 13 amino acid fragment
within GPIba. This fragment can be present as a single
copy or repeated up to four times. By increasing the length
of GPIba, VNTR is hypothesized to facilitate platelet
interaction with the subendothelial matrix and predispose
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affected individuals to increased thrombotic risk (3). Finally,
a T to C single nucleotide substitution at position 25 from
the ATG start codon characterizes the Kozak sequence
polymorphism. Although it does not alter structure, the
Kozak polymorphism may increase surface expression of
GPIba (2,4). In one study, GPIb-IX-V receptor density on
the platelet surface correlated with genotype; TT homozy-
gous platelets expressed the least GPIba, whereas CC
homozygous platelets expressed the most (4). Importantly,
these findings have not been verified in subsequent research
(5).
Adding to the controversy over platelet polymorphisms
are studies associating GPIba variants with an increased risk
of ischemic events (6–8). The interpretation of these
studies is further blurred by variations in study design,
patient demographics and clinical presentation. In this issue
of the Journal, Meisel et al. (2) add to our understanding of
the GPIba receptor as a potential risk factor for coronary
artery disease and adverse events complicating catheter-
based interventions. In this case-controlled study, the in-
vestigators genotyped nearly 1,000 patients with coronary
artery disease and compared the frequency of the Kozak
polymorphism to matched controls. In a second part, they
examined the role of the 25C allele as a predictor of
short-term complications following percutaneous coronary
interventions. Compared to the wild-type allele (25T/T),
carriers of the 25C allele were more likely to present with
an unstable coronary syndrome and/or experience a peri-
procedural adverse event following balloon angioplasty.
Unlike previous studies examining the role of the 25C
allele in ischemic heart disease, the study by Meisel et al. (2)
is the first to associate the GPIba polymorphism with an
increased risk of developing an unstable coronary syndrome
or ischemic complication following percutaneous coronary
intervention. Among nearly 2,500 patients undergoing an-
gioplasty, Santoso et al. (9) found no relationship between
the Kozak polymorphism and ischemic events, except for
possibly a greater severity of coronary artery disease in
younger patients who were homozygous with the 25C
allele. Still other smaller studies have failed to confirm the
association between the Kozak sequence polymorphism and
ischemic events (10,11).
Exactly why carriers of the 25C allele experience a higher
rate of adverse events following balloon angioplasty, but not
after atherectomy or stenting, is puzzling. As the investiga-
tors hypothesized, it seems intuitive that any mutation
promoting platelet adhesion would increase the risk of
complications following a procedure that intentionally dis-
rupts the endothelium. However, the increased risk associ-
ated with the Kozak polymorphism is found only with
balloon angioplasty and not with other interventions known
to injure the endothelium or involve angioplasty (e.g.,
predilation with balloon angioplasty prior to stenting).
Moreover, established predictors of adverse events following
catheter-based interventions (e.g., diabetes, lesion morphol-
ogy, among others) vary considerably among the groups in
the present study, and the use of GPIIb-IIIa inhibitors
(known to reduce periprocedural ischemic complications)
was not specified. Although we do not have a molecular
mechanism to explain the discrepancy between various
angioplasty procedures relative to the Kozak polymorphism,
the data, if confirmed, could be useful in the selection of the
appropriate procedure for individual patients.
PlA2 polymorphism of GPIIIa. Glycoprotein IIIa, to-
gether with GPIIb, constitutes the fibrinogen receptor
(GPIIb-IIIa, or integrin a2b3), whose engagement repre-
sents the final common pathway for platelet aggregation
(Fig. 2). Due to the substitution of a cytosine for a
thymidine at position 1565 in exon 2 of the GPIIIa gene,
the platelet antigen 2 (PlA2) variant displays a proline
instead of a leucine at amino acid 33. The structural change
in GPIIb-IIIa that is induced by the PlA2 variant is the
Figure 1. The initial phase of primary hemostasis occurs with the adhesion of platelets via the glycoprotein (GP)Ib-IX-V receptor complex to von
Willebrand factor (vWf) located on the subendothelial matrix (Step 1). Released from Weibel-Palade (WPB) bodies located within endothelial cells (EC),
vWf complexes in the presence of oxidants to bind the GPIb-IX-V integrin receptor on the disrupted endothelial surface. The interaction of vWf with
platelets at the site of endothelial injury immobilizes platelets under conditions of high shear stress. GPV 5 glycoprotein V.
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cause for a severe form of neonatal alloimmune thrombo-
cytopenia.
Similar to the GPIba polymorphism, PlA2 has been
implicated in arterial thrombosis and the development of
unstable coronary syndromes. Specifically, a high prevalence
of the PlA2 allele has been reported in patients with unstable
angina or myocardial infarction (MI) and in siblings of
patients with a history of premature ischemic heart disease
(12,13). Mikkelson et al. (14) also reported a higher
prevalence of PlA2 among victims of sudden cardiac death
whose coronary arteries contained thrombus. Still other
studies have not confirmed the association between PlA2 and
MI (15), maintaining the controversy over the influence of
the PlA2 polymorphism. Despite the variance in epidemio-
logic data, most studies examining the molecular effect of
the PlA2 polymorphism on GPIIb-IIIa function have been
consistent, showing that the mutation results in increased
platelet responsiveness (16,17).
Platelet antigen 2 polymorphism has also been related to
a higher incidence of adverse ischemic events following
catheter-based procedures. As previously described,
catheter-based interventions with coronary stenting are a
major stimulus for platelet activation. Although the use of
intracoronary stents has improved both short- and long-
term clinical outcomes by maximizing acute procedural
luminal gain and reducing the incidence of restenosis, the
disruption of the endothelium and the placement of a
metallic stent promote platelet adhesion and thrombus
formation. Both platelet adhesion and aggregation also
contribute substantially to restenosis by promoting the
migration and growth of smooth muscle cells. Walter et al.
(18) reported a higher incidence of acute stent thrombosis
and MI among PlA2-positive individuals following percuta-
neous revascularization. Although the incidence of stent
thrombosis did not vary with PlA1/A2 status, Kastrati et al.
(19) found that PlA2 carriers were more likely to experience
periprocedural death and Q-wave MI. In a multivariate
model, the risk of an adverse event after coronary stenting
was approximately 2.5 times for PlA2 homozygous individ-
uals compared to the PlA1/A1 genotype. Among 653 patients
undergoing either coronary stenting or directional coronary
atherectomy, Laule et al. (20) observed a trend toward worse
30-day outcomes following intervention for PlA2-positive
individuals, though these results did not achieve statistical
significance.
Although these studies differ in their conclusion relative
to the strength of the impact of PlA2 on adverse events,
substantial differences in the design and end points among
the studies must be noted. In addition, the antithrombotic
regimen varied considerably among these studies. We have
previously reported on the gradual beneficial effect of
improved antiplatelet regimens on the occurrence of throm-
boembolic complications in stent patients displaying the
PlA2 polymorphism (21). Hence, with the use of thienopy-
ridine derivatives and GPIIb-IIIa blockers, outcome differ-
ences between PlA1/A1 homozygous and PlA1/A2 heterozy-
gous individuals seem to become blurred. However, PlA2/A2
homozygous patients appear to remain at higher risk despite
therapeutic advances (19,22).
GPIa polymorphisms. The two polymorphisms in the
gene for GPIa occur at nucleotides 807 (C or T) and 873 (G
or A) and are associated with up to 10-fold variation in
receptor density on the platelet surface. Because these
polymorphisms do not result in an amino acid substitution,
they are considered silent polymorphisms and do not
produce alloantigens. A third polymorphism at nucleotide
1642 results in the substitution of glutamic acid for lysine.
Despite the possibility that these polymorphisms may result
in an increased number of collagen receptors on the platelet
surface, studies examining the role of GPIa mutations in
acute coronary syndromes have reported conflicting results
(23–25).
Figure 2. Platelet activation in the presence of collagen and other agonists triggers a conformational change in the platelet and increased glycoprotein
(GP)IIb/IIIa receptor expression on the platelet surface. Fibrinogen binding to GPIIb/IIIa results in cross-linking of platelets bound to the subendothelial
matrix of a disrupted atherosclerotic plaque via von Willebrand factor (vWf) (Step 2). The process of platelet aggregation may be effectively inhibited by
clinical use of GPIIb/IIIa blockade.
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TRANSLATING GENETIC
STUDIES INTO CLINICAL PRACTICE
With so many conflicting results from epidemiologic studies
of platelet polymorphisms, how should clinicians interpret
the findings by Meisel et al. (2)? Should health care
providers begin potentially costly screening programs to
predict cardiovascular risk or instead dismiss these results as
inconclusive evidence? Although it is appealing to attribute
much of the disagreement among studies to design or
patient populations, it is also important to recognize that
the clinical diagnosis of acute coronary syndromes includes
a broad range of phenotypic characteristics. Moreover, the
relative impact of platelet polymorphism such as GPIba
may vary according to multiple factors such as age, gender,
smoking history, diabetes or medications. Although platelet
polymorphisms are a promising addition to more estab-
lished cardiovascular risk factors, identifying genetic vari-
ants as a single cause of cardiovascular disease would be an
oversimplification; instead, the contribution of these poly-
morphisms should also be considered in the context of
nongenetic factors.
It appears most appropriate to accept the present study as
part of a growing body of evidence to define the role of
inherited platelet polymorphisms in cardiovascular disease.
To date, no single trial has conclusively established the
importance of platelet polymorphisms. Until a large data-
base involving thousands of patients is able to reconcile
divergent findings satisfactorily, the controversy will remain.
Considering inheritance patterns, the accuracy of genotyp-
ing and the impact of environmental factors, the required
sample size to have adequate power has been estimated to
include several thousands of patients (26). Therefore, stud-
ies should encourage carefully supervised genetic sampling
as part of larger clinical trials or even routine patient care to
create larger databases.
Aside from describing a relationship between platelet
polymorphisms and cardiovascular disease, such studies
should also motivate scientists to define the biologic effects
of inherited platelet traits more accurately. In the case of
GPIba, for example, there is uncertain evidence whether
the mutation definitely results in a greater number of
platelet membrane receptors. Understanding the interaction
of platelet polymorphisms with cardiovascular risk factors
and endovascular procedures may also influence treatment
strategies targeting a specific susceptibility gene implicated
in coronary thrombosis. Considering the increased risk of
the PlA2 polymorphism for adverse events in patients
undergoing coronary stenting, affected patients might ben-
efit from a more intensive antithrombotic regimen of
extended therapy with both aspirin and clopidogrel (21).
Platelets from PlA2-positive patients may be more resistant
to inhibition with aspirin than those from PlA1/A1 homozy-
gous patients in the presence of collagen. However, treat-
ment with the combination of aspirin and clopidogrel in
PlA2-positive patients appears to attenuate collagen-induced
platelet aggregation, such that their platelet inhibition is no
longer different from that of PlA1/A1 patients receiving
aspirin alone (P. J. Goldschmidt-Clermont, personal com-
munication, 2001). In addition, statin therapy following
coronary stenting may abolish the increased incidence of
restenosis observed among PlA2 carriers compared to
PlA1/A1 homozygotes (27).
Despite the substantial research activity in the genetics of
coronary artery disease, relatively little coordinated effort has
been made to confirm the associated risks of specific gene
polymorphisms. As a result, identifying risk associated with
genetic discoveries and translating this knowledge into
clinical practice will likely occur gradually rather than by one
revolutionary discovery. To solve this problem, future stud-
ies should consist of larger studies that adhere to the same
standards as contemporary large-scale randomized trials for
drug development. Including mechanistic studies as part of
clinical trials will also facilitate our understanding of the
functional significance of these polymorphisms, help define
the impact of these mutations on clinical outcomes and
validate case-control association studies. A spin-off effect of
these studies might be a better definition of phenotypes for
the group of syndromes that we have somewhat arbitrarily
assembled under the generic name of “acute coronary
syndromes.” Only through a larger collective effort will the
role of platelet polymorphisms and other susceptibility
genes for cardiovascular disease be defined. Then, the
translation of the human genome project into information
that is directly relevant to the betterment of our patients
may become a reality. Just as the “butterfly flapping its wings
today produces a tiny change in the state of the atmosphere”
(1), the impact of slight changes within relevant genes for
heart disease will become, once and for all, measurable.
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